Top

Published in:

01-09-2017 | Case Report

Anticoagulation therapy for a LVAD patient with acquired warfarin resistance

Authors: Daisuke Yoshioka, Koichi Toda, Takayuki Hidaka, Soichiro Yasuda, Shunsuke Saito, Keitaro Domae, Yoshiki Sawa

Published in: Journal of Artificial Organs | Issue 3/2017

Abstract

Anticoagulation therapy with warfarin is essential for postoperative management in patients with left ventricular assist device (LVAD). In this manuscript, we report the case of a patient who developed warfarin resistance after LVAD implantation. Although we administered a novel anticoagulant drug in addition to warfarin and aspirin therapy, the patient developed a major stroke. The patient needed continuous intravenous heparinization until heart transplantation for approximately 2 years. Meticulous management of anticoagulation therapy is essential for a LVAD with warfarin resistance. To our best knowledge, our case is the first case of warfarin resistance in a patient with LVAD.

Wever-Pinzon O, Naka Y, Garan AR, Takeda K, Pan S, Takayama H, et al. National trends and outcomes in device-related thromboembolic complications and malfunction among heart transplant candidates supported with continuous-flow left ventricular assist devices in the United States. J Heart Lung Transplant. 2016;35:884–92.CrossRefPubMed

Topkara VK, Knotts RJ, Jennings DL, Garan AR, Levin AP, Breskin A, et al. Effect of CYP2C9 and VKORC1 gene variants on warfarin response in patients with continuous-flow left ventricular assist devices. ASAIO J. 2016;62:558–64.CrossRefPubMed

KE OS, Meany B, Hurley JP. Warfarin resistance due to VKORC1 gene mutation in a patient following mechanical aortic valve replacement with an ON-X valve. Int J Cardiol. 2015;188:63–4.CrossRef

Yasar AS, Balbay Y, Maden O, Sasmaz H. Early mechanical mitral valve thrombosis in a patient with warfarin resistance. J Heart Valve Dis. 2007;16:200–2.PubMed

Loebstein R, Dvoskin I, Halkin H, Vecsler M, Lubetsky A, Rechavi G, et al. A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood. 2007;109:2477–80.CrossRefPubMed

Gellatly RM. Intravenous warfarin as an alternative for anticoagulation. Pharmacotherapy. 2007;27:933–5.CrossRefPubMed

Terrovitis JV, Ntalianis A, Kapelios CJ, Vakrou S, Diakos N, Katsaros L, et al. Dabigatran etexilate as second-line therapy in patients with a left ventricular assist device. Hellenic J Cardiol. 2015;56:20–5.PubMed

Title: Anticoagulation therapy for a LVAD patient with acquired warfarin resistance
Authors: Daisuke Yoshioka
Koichi Toda
Takayuki Hidaka
Soichiro Yasuda
Shunsuke Saito
Keitaro Domae
Yoshiki Sawa
Publication date: 01-09-2017
Publisher: Springer Japan
Published in: Journal of Artificial Organs / Issue 3/2017
Print ISSN: 1434-7229
Electronic ISSN: 1619-0904
DOI: https://doi.org/10.1007/s10047-017-0947-8

At a glance: The STEP trials

Springer Medicine

Anticoagulation therapy for a LVAD patient with acquired warfarin resistance

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2017

Temporary biventricular support with extracorporeal membrane oxygenation: a feasible therapeutic approach for cardiogenic shock with multiple organ failure

Non-machinery dialysis that achieves blood purification therapy without using full-scale dialysis machines

Bedside repositioning of a dislocated Avalon-cannula in a running veno-venous ECMO

Extracorporeal cytokine elimination as rescue therapy in refractory septic shock: a prospective single-center study

Total artificial heart implantation for biventricular failure due to eosinophilic myocarditis

Artificial hearts—recent progress: republication of the article published in the Japanese Journal of Artificial Organs